News

MedPage Today on MSN1d
Monotherapy for CLL
The initial report of monotherapy with the BCL-2 inhibitor venetoclax showed it had durable clinical activity and favorable ...
MedPage Today on MSN1d
Adding Polivy to Standard of Care Boosts Survival in Relapsed/Refractory DLBCL
Adding polatuzumab vedotin (Polivy) to standard-of-care treatment significantly improved overall survival (OS) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), the phase ...
Medscape2d
Pola-R-GemOx Boosts Survival in R/R DLBCL
Data from the POLARGO trial potentially establishes a new standard of care for patients with R/R DLBCL ineligible for ...
Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven By Increasing Cancer Incidences - Financial News Media
The global oncology market is undergoing rapid growth, mainly due to the increasing number of cancer cases around the world. The World Health Organization estimates there will be over 35 million new ...
TMCnet6d
Global Billion Dollar Oncology Industry Experiencing Substantial Growth Driven by Increasing Cancer Incidences
FN Media Group News Commentary - The global oncology market is undergoing rapid growth, mainly due to the increasing number of cancer cases around the world. The World Health Organization estimates ...